Amicus Therapeutics, Inc. $FOLD Holdings Raised by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in Amicus Therapeutics by 4.1%, acquiring an additional 105,856 shares, bringing their total ownership to approximately 2.66 million shares valued at $21.7 million.
• A number of institutions have made significant moves regarding Amicus Therapeutics shares, including GAMMA Investing LLC, which raised its holdings by over 1,610% in the first quarter.
• Analyst ratings for Amicus Therapeutics vary, with Morgan Stanley upgrading the stock to "overweight" while others, like Goldman Sachs, lowered their price target from $12 to $9, leading to a current consensus rating of "Moderate Buy."

Invesco Ltd. boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,661,394 shares of the biopharmaceutical company's stock after buying an additional 105,856 shares during the quarter. Invesco Ltd. owned 0.86% of Amicus Therapeutics worth $21,717,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of FOLD. Virtus Fund Advisers LLC bought a new position in Amicus Therapeutics in the fourth quarter worth about $29,000. PNC Financial Services Group Inc. boosted its stake in Amicus Therapeutics by 211.4% in the first quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares during the period. GF Fund Management CO. LTD. acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $59,000. GAMMA Investing LLC boosted its stake in Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares during the period. Finally, Bryce Point Capital LLC acquired a new position in Amicus Therapeutics in the first quarter valued at approximately $100,000.

Wall Street Analysts Forecast Growth

FOLD has been the subject of a number of research reports. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. UBS Group lifted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Finally, The Goldman Sachs Group decreased their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock traded up $0.04 on Tuesday, hitting $7.52. The company had a trading volume of 2,919,436 shares, compared to its average volume of 4,428,290. The business has a 50-day simple moving average of $6.42 and a 200-day simple moving average of $7.15. The company has a debt-to-equity ratio of 1.92, a current ratio of 3.21 and a quick ratio of 2.29. The company has a market cap of $2.32 billion, a PE ratio of -62.66 and a beta of 0.53. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.